SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-188577
Filing Date
2022-07-06
Accepted
2022-07-06 16:10:58
Documents
12
Period of Report
2022-07-06
Items
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K d259130d8k.htm   iXBRL 8-K 26986
  Complete submission text file 0001193125-22-188577.txt   149190

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA ctmx-20220706.xsd EX-101.SCH 2842
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE ctmx-20220706_lab.xml EX-101.LAB 17995
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ctmx-20220706_pre.xml EX-101.PRE 11252
6 EXTRACTED XBRL INSTANCE DOCUMENT d259130d8k_htm.xml XML 3370
Mailing Address 151 OYSTER POINT BLVD. SUITE 400 SOUTH SAN FRANCISCO CA 94080
Business Address 151 OYSTER POINT BLVD. SUITE 400 SOUTH SAN FRANCISCO CA 94080 650.515.3185
CytomX Therapeutics, Inc. (Filer) CIK: 0001501989 (see all company filings)

IRS No.: 273521219 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37587 | Film No.: 221068791
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences